NC
CLLS

Nexthera Capital’s Cellectis CLLS Stock Holding History

Nexthera Capital’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-548,212
Closed -$15.5M – 57
2018
Q2 		$15.5M Buy
548,212
+215,458
+65% +$6.42M 2.4% 13
2018
Q1 		$10.5M Buy
+332,754
New +$10.5M 1.73% 21

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Nexthera Capital's CLLS Position: Q3 2018 in Review

Nexthera Capital sold out of Cellectis (CLLS) in Q3 2018, closing a stake of 548,212 shares — an estimated $15.5M sold.

Nexthera Capital first reported a position in CLLS in Q1 2018 and held it in 2 quarters. The position peaked at $15.5M in Q2 2018. 81 funds tracked by Wall St. Rank hold CLLS as of Q3 2018.

  • Nexthera Capital reported no remaining Cellectis position as of Q3 2018 after selling out during the quarter.
  • Nexthera Capital sold 548,212 Cellectis shares in Q3 2018, an estimated $15.5M.
  • Nexthera Capital first reported a position in Cellectis in Q1 2018 and held it in 2 quarters.
  • Nexthera Capital's Cellectis position peaked at $15.5M in Q2 2018.
  • 81 funds tracked by Wall St. Rank held Cellectis as of Q3 2018.

Based on Nexthera Capital's 13F filing for Q3 2018, filed 14 Nov 2018.